EFPIA anxious over EMA relocation disruption

While countries bidding to become the new home to the European Medicines Agency (EMA) are excited at the chance its likely relocation from London offers them following Brexit, a group representing the continent’s pharma associations has expressed anxiety at potential disruption the move may cause.

This month’s news that the transfer of the agency away from its current home would be a given in the discussions on the UK’s exit from the European Union (EU) appeared to all but confirm that the EMA would be moving to a new location in another member state.

"Were a rapid resolution on the future location of the EMA not to materialize, the extent of the severe and significant negative repercussions for public and animal health in Europe would be indeterminable"